Current Report Filing (8-k)
May 29 2020 - 4:04PM
Edgar (US Regulatory)
false 0001439222 0001439222 2020-05-29 2020-05-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2020
Agios Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36014
|
|
26-0662915
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
88 Sidney Street, Cambridge, MA
|
|
02139
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (617) 649-8600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, Par Value $0.001 per share
|
|
AGIO
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On May 29, 2020, Agios Pharmaceuticals, Inc. (the “Company”) issued a press release announcing updated data from the ongoing phase 1 study evaluating single agent vorasidenib in isocitrate dehydrogenase-mutant advanced solid tumors, including glioma. The Company presented data from the non-enhancing glioma population at the American Society of Clinical Oncology (ASCO) Annual Meeting. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
AGIOS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
Date: May 29, 2020
|
|
|
|
By:
|
|
/s/ Jacqualyn A. Fouse
|
|
|
|
|
|
|
Jacqualyn A. Fouse, Ph.D.
Chief Executive Officer
|
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024